{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:44:10Z","timestamp":1762875850745,"version":"3.37.3"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR\u201011\u2010PHUC\u2010001"],"award-info":[{"award-number":["ANR\u201011\u2010PHUC\u2010001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The risk of venous thromboembolic event (VTE) in multiple myeloma is particularly increased. Current guidelines recommend systematic VTE prophylaxis with vitamin K antagonists (VKA) or low weight molecular heparin (LWMH) or unfractionated heparin (UFH) in high\u2010risk patients, based on treatment received [e.g. use of IMiDs (thalidomide, lenalidomide and pomalidomide), alkylating agents or erythropoietin] and individual risk factors (e.g. history of VTE). The aim of this study was to describe strategy of VTE prophylaxis and prescribing of other antithrombotic agents during the first 6\u00a0months of multiple myeloma therapy, with stratification on IMiD\u2010based regimens and drug and disease\u2010related risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study of French beneficiaries from the health insurance database (SNIIRAM, Syst\u00e8me National d'Information Inter\u2010R\u00e9gime de l'Assurance Maladie) was designed in the Midi\u2010Pyr\u00e9n\u00e9es area (South West France). Patients starting a treatment for multiple myeloma in the period 2011\u20132014 were identified through hospital and chronic disease diagnoses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 236 incident multiple myeloma patients, 56% male (<jats:italic>n<\/jats:italic>\u00a0=\u00a0133), 67% &gt;65\u00a0years (<jats:italic>n<\/jats:italic>\u00a0=\u00a0159) and 47% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0110) patients received an IMiD\u2010based regimen. In these patients, 63% (<jats:italic>n<\/jats:italic>\u00a0=\u00a069) were identified as high\u2010risk patients with indication for low molecular weight heparin or equivalent, and 37% (<jats:italic>n<\/jats:italic>\u00a0=\u00a041) were identified as low\u2010risk with aspirin recommended. Among the high\u2010risk IMiDs patients, 43% (30\/69) currently received a VTE prophylaxis after starting their first regimen: 70% LWMH (21\/30), 40% VKA (12\/30), 10% UFH (3\/30) and 13% (4\/30) other drugs (rivaroxaban and fondaparinux); 33% of the patients (23\/69) received an antiplatelet drug only, and 23% (16\/69) did not receive any antithrombotic drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results revealed lack of implementation of VTE prophylaxis in one out of high\u2010risk multiple myeloma patients with IMiD. Copyright \u00a9 2017 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4180","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T05:26:43Z","timestamp":1487136403000},"page":"578-586","source":"Crossref","is-referenced-by-count":20,"title":["Real\u2010life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the <scp>French<\/scp> health insurance database"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-9224","authenticated-orcid":false,"given":"Aurore","family":"Palmaro","sequence":"first","affiliation":[{"name":"Medical and Clinical Pharmacology department Toulouse University Hospital  Toulouse France"},{"name":"UMR INSERM 1027 University of Toulouse  Toulouse France"},{"name":"CIC 1436 Toulouse University Hospital  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Eve","family":"Roug\u00e9\u2010Bugat","sequence":"additional","affiliation":[{"name":"UMR INSERM 1027 University of Toulouse  Toulouse France"},{"name":"Academic Department of Family Medicine, Faculty of Medicine Toulouse University of Toulouse  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Department of Haematology Toulouse University Hospital  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology department Toulouse University Hospital  Toulouse France"},{"name":"UMR INSERM 1027 University of Toulouse  Toulouse France"},{"name":"CIC 1436 Toulouse University Hospital  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Moulis","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology department Toulouse University Hospital  Toulouse France"},{"name":"UMR INSERM 1027 University of Toulouse  Toulouse France"},{"name":"CIC 1436 Toulouse University Hospital  Toulouse France"},{"name":"Department of Internal Medicine Toulouse University Hospital  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology department Toulouse University Hospital  Toulouse France"},{"name":"UMR INSERM 1027 University of Toulouse  Toulouse France"},{"name":"CIC 1436 Toulouse University Hospital  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102003\u201040965"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2011.04215.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12070"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26302"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064444"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.11.018"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8197"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2008.07577.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.12.002"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201002\u2010140434"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12071"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201008\u2010375089"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.214"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2011.04215.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201004\u2010277467"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201012\u2010257519"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400015675"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612452291"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2013.01.015"},{"key":"e_1_2_8_27_1","first-page":"1","article-title":"The development of CCAM: the new French coding system of clinical procedures","volume":"31","author":"Trombert\u2010Paviot B","year":"2003","journal-title":"HIM J"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4006"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13\u201002\u20100140"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069328"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215569555"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12013"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.03.006"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010008\u20100561\u20101"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201005\u2010578336"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.5600\/mmrr.003.04.a01"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1188\/08.CJON.S1.21\u201027"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)60202\u20100"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060115"},{"key":"e_1_2_8_40_1","first-page":"281","article-title":"Thromboprophylaxis in myeloma: what is happening outside of clinical trials?","volume":"107","author":"Crowley MP","year":"2014","journal-title":"Ir Med J"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH08\u201003\u20100193"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2015.07.003"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7550"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2006.01928.x"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701647887"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201008\u2010303487"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(09)70284\u20100"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4180","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:16:28Z","timestamp":1696504588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/pds.4180"],"URL":"https:\/\/doi.org\/10.1002\/pds.4180","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}